It will also be interesting to see whether these outcomes can be further improved once more targeted BH3-mimetics (e.g. through conjugation to tumour-specific antibodies) are developed and which could potentially allow safe co-treatment with BCL-XL plus MCL-1 direct inhibitors. This evidence concerns the gene BCL2L1 and neoplasm.